Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy In Deeper Trouble As Apotex Seeks Declaratory Judgment On Valtrex, Aricept Exclusivity; Will Nexium and Lipitor Be Next In Line?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - U.S. FDA's punitive actions against Ranbaxy's manufacturing units in India is set to hit the company where it hurts most. Ranbaxy's 180-day exclusivity status for anti-herpes drug Valtrex (valacylovir) is in trouble as Canadian generic drug maker Apotex has sought a declaratory judgment on the drug that "will start the running of Ranbaxy's 180-day exclusivity period, even if Ranbaxy has yet to market its product.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts